BioSpace News Archive

Vivoryon Therapeutics AG, announced that they have entered into a research collaboration with University Medical Center Schleswig-Holstein, Campus Kiel, to discover and develop first-in-class therapeutics in cancer immunotherapy.

Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces a pre-close trading update for the 12 months ended 30 June 2019 and the successful outcome of the litigation related to the Grass MATA MPL Phase II trial.

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.

Pain, fluids, odor—and endless dressing changes: Chronic wounds often fail to close, and patients’ bodies appear unable to heal.

Speak up and be heard—never before have these words pertained to lab work quite the way they do now: thanks to COATINO™, the first digital laboratory assistant that Evonik is developing especially for the coatings industry.

Driving personalized, immune-based therapy to target patients’ own immune responses

In a paper published in the Journal of Molecular Neuroscience scientists at Boston University School of Medicine have shown that increasing the levels of the naturally occurring Klotho protein reduces the neurological deficits and prolongs life span in an experimental model of Amyotrophic Lateral Sclerosis also known as Lou Gehrig’s disease.The leading scientists on this study are also affiliated with Klogene Therapeutics, Inc.

Current cancer control efforts in the United States typically are fragmented and uncoordinated, but taking a systems approach to establish a U.S. National Cancer Control Plan would address the challenge more holistically, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16.

Sartorius Stedim Biotech (SSB) launched a new vessel for its ambr® 250 modularbenchtop automated mini bioreactor system.